Sign in

CIK 0001651308

  • Large accelerated filer

BeOne Medicines Ltd.

Sign in to watch
Ticker
BEIGF
Exchange
Nasdaq, OTC
Industry
Pharmaceutical Preparations
FY end
Dec 31
Entity type
Operating
EIN
981209416
Phone
+41 616851900
Business address
C/O BEONE MEDICINES I GMBH, AESCHENGRABEN 27, 21ST FLOOR, BASEL, Switzerland, 4051
Former names
BeiGene, Ltd.

Securities

  • ONC American Depositary Shares Nasdaq
  • BEIGF Common stock OTC
  1. 4 Grant or award Director acquired 18,980 shares (grant or award)
  2. 4 Grant or award Director acquired 18,980 shares (grant or award)
  3. 4 Grant or award Director acquired 18,980 shares (grant or award)
  4. 3 Insider Initial Statement of Ownership
  5. 3 Insider Initial Statement of Ownership
  6. 4 Grant or award Director acquired 37,960 shares (grant or award)
  7. 4 Open-market sale Principal Accounting Officer sold 136 shares at an average $271.33 ($36,901)
  8. 4 Open-market sale SVP, General Counsel sold 871 shares at an average $270.42 ($235,539)
  9. 4 Open-market sale President, Global Head of R&D sold 1,367 shares at an average $269.38 ($368,247)
  10. 4 Open-market sale President and COO sold 1,484 shares at an average $269.37 ($399,738)
  11. 4 Open-market sale Chief Executive Officer sold 4,940 shares at an average $270.56 ($1,336,548)
  12. 4 Open-market sale Director sold 235 shares at $279.13 ($65,596)
  13. 4 Open-market sale Director sold 212 shares at $309.51 ($65,617)
  14. 4 Open-market sale Director sold 212 shares at $309.60 ($65,636)
  15. 4 Open-market sale Director sold 212 shares at $309.59 ($65,633)
  16. 4 Open-market sale Director sold 10,998 shares at an average $23.82 ($261,981)
  17. 3/A Insider 3/A
  18. 4 Planned sale SVP, General Counsel sold 332 shares at $310.72 ($103,159)
  19. 4 Planned sale SVP, General Counsel sold 332 shares at $311.59 ($103,448)
  20. 4 Planned sale SVP, General Counsel sold 341 shares at $300.00 ($102,300)

Page 3 of 29 · 580 filings